# Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma

> **NCT01900743** · PHASE2 · COMPLETED · sponsor: **Centre Oscar Lambret** · enrollment: 219 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01900743
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-05
- **Primary completion:** 2020-09-16
- **Final completion:** 2020-09-16
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900743, "Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01900743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*